Roche Holding (SWX:ROG) Valuation Check After Key FDA And Phase III Milestones [Yahoo! Finance]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Yahoo! Finance
Roche Holding (SWX:ROG) is back in focus after the US FDA accepted its New Drug Application for giredestrant in advanced ER positive breast cancer, alongside positive phase III data for Gazyva in primary membranous nephropathy. See our latest analysis for Roche Holding. Roche Holding's recent product milestones appear to have coincided with a pickup in momentum, with a 30 day share price return of 7.44% and a 90 day share price return of 19.53%. The 1 year total shareholder return sits at 29.09%, signalling medium term performance alongside longer term total shareholder returns over 3 and 5 years. If this kind of late stage pipeline news has your attention, it could be a good moment to scan our list of 113 healthcare AI stocks as another way to find healthcare names exposed to advanced therapies and diagnostics. With shares up strongly over the past year, a value score of 5, and an estimated intrinsic value suggesting a sizable discount, investors now have to ask: Is Roche st
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Nykode Therapeutics AS (VACBF) Q4 2025 Earnings Call Highlights: Navigating Financial ... [Yahoo! Finance]Yahoo! Finance
- Parker Institute for Cancer Immunotherapy Announces Appointment of Bob Purcell as Chief Communications Officer [Yahoo! Finance]Yahoo! Finance
- BreezeBio banks $60M to make more precise genetic medicines [Yahoo! Finance]Yahoo! Finance
- Flatiron Health Attends the 2026 American Society of Genitourinary Cancers Symposium to Answer Oncology's Most Critical QuestionsBusiness Wire
- FDA Approves Genentech’s Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic LeukemiaBusiness Wire